迈克生物：10月24日召开董事会会议

Group 1 - The core point of the article is that Maike Biological (SZ 300463) announced the convening of its sixth board meeting to review the third quarter report for 2025, with a focus on its revenue structure being entirely from in vitro diagnostics [1][1][1] - As of the report, Maike Biological has a market capitalization of 7.1 billion yuan [1][1][1] Group 2 - The company’s revenue for the first half of 2025 is entirely derived from in vitro diagnostics, indicating a focused business model [1][1][1] - The board meeting was held on October 24, 2025, combining both in-person and remote participation [1][1][1]